Skip to main content
Clinical Trials/NCT05507554
NCT05507554
Unknown
Not Applicable

Effectiveness of Different Postoperative Analgesics Use in the Management of Acute Pain After Ureteroscopy.

Pakistan Kidney and Liver Institute and Research Center1 site in 1 country176 target enrollmentAugust 1, 2022

Overview

Phase
Not Applicable
Intervention
Opioid
Conditions
Post Operative Pain
Sponsor
Pakistan Kidney and Liver Institute and Research Center
Enrollment
176
Locations
1
Primary Endpoint
Pain score in post op period at 1 hour.
Last Updated
3 years ago

Overview

Brief Summary

In this study, we will see the feasibility of a non-opioid pain killers in management of acute post-operative period as well as on discharge from the hospital compared to opioid medications for postoperative pain following URS and stent placement.

The objective of this study will be to compare the pain control effects of no opioid and opioid pain killers during the post-operative period. This study will be a Randomized Clinical trial. Data will be collected from department of Urology, PKLI, Lahore. All patients included in this study will undergo ureteroscopic laser lithotripsy of ureter stones. One group will receive tramadol (opioid) while other two groups will receive Paracetamol and diclofenac sodium (NSAIDs) respectively. All subjects will receive one of the three pain killers after ureteroscopy procedure for ureter stones in a randomized fashion. Postoperative pain intensity will be measured by the investigator and the nurse in the first hour after the surgery in the recovery room and then in urology ward at 1,6, 12, 24, 48, & 72 hours using the Numeric Pain Intensity Scale (NPIS).A mean pain score of less than 2 for each category of surgical procedures or analgesics group will be defined as satisfactory pain control. The data will be analyzed using SPSS v 24.

Detailed Description

Achieving adequate postoperative pain relief should be a definitive goal of patient care in any surgery because pain is one of the most common postoperative symptoms as reported from previous studies. Efforts have begun to implement non opioid protocols for outpatient urologic surgery. Recently it was found that Ureteroscopy (URS) with stent placement is possible without using postoperatve opioids for pain control and stent-related symptoms. To date, attention has focused on the problems of opioid abuse, diversion, and overdose. These issues pertain primarily to those who are already suffering from substance use disorders. More recently, the possibility that legitimate use of prescription opioids has led to incident substance use disorders (iatrogenic addiction) is beginning to gather attention. When iatrogenic addiction has been considered, it is almost exclusively in the context of chronic pain. Not surprisingly, emergency providers commonly believe that short courses of opioid therapy for acute pain are safe and that their role in the current opioid crisis is limited to attenuating diversion. However, several recent studies have demonstrated that short course opioid therapy for acute pain is associated with future recurrent use of opioids, raising the possibility that short course opioid therapy may be a potential trigger for the onset of opioid related substance use disorders. If so, there are considerable health implications as more than 1 in every 6 patients discharged from an ED are given a prescription for an opioid pain reliever. In this study, we will see the feasibility of a non-opioid discharge protocol compared to standard opioid medications for postoperative pain following URS and stent placement. We will also evaluate the effect of these analgesic in acute pain management in post op stay in hospital.

Registry
clinicaltrials.gov
Start Date
August 1, 2022
End Date
December 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pakistan Kidney and Liver Institute and Research Center
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ureteroscopy procedure performed for ureteric stones between age 18 -60 years.
  • Patients with normal Renal and Liver function tests function tests.
  • Patients having no growth on urine culture will be included in this study.
  • Patients with no previous history of ureteroscopy procedure in past.

Exclusion Criteria

  • Patients having history of allergic reaction to any type of the drugs to be used in the study.
  • If Paracetamol contraindicated in severe hepatic impairment, or severe active hepatic disease.
  • If Diclofenac contraindicated in compromised renal function, increased risk of bleeding due to clotting disorder, an increased risk of bleeding, gastric ulcers, alcoholism.
  • If tramadol is contraindicated as in alcoholism, depression and drug abuse.
  • When a patient has a history of opioid abuse.
  • When a patient refuses to participate in the study.
  • When patient is unable to give consent.
  • If the patient has used conventional NSAIDs, Acetaminophen or Tramadol during the 6 hours before surgery,

Arms & Interventions

Opioid Group

This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Tramadol 50 mg. They will also be discharged on Tramadol oral capsule 50 mg for postoperative pain after the ureteroscopy procedure with stent placement

Intervention: Opioid

Paracetamol (Acetaminophen) Group

This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Paracetamol 1 Gram. They will also be discharged on oral Tablet Paracetamol 1 Gram for postoperative pain after the ureteroscopy procedure with stent placement

Intervention: Non-Opioid Analgesic

Diclofenac Sodium Group

This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intra muscular injection Diclofenac Sodium 50 mg. They will also be discharged on oral Tablet Diclofenac Sodium 50 mg for postoperative pain after the ureteroscopy procedure with stent placement.

Intervention: Non-Opioid

Outcomes

Primary Outcomes

Pain score in post op period at 1 hour.

Time Frame: [1 hour]

Pain score assessment at one hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Pain score in post op period at 6 hour.

Time Frame: [6 hour]

Pain score assessment at six hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Pain score in post op period at 12 hour.

Time Frame: [12 hour]

Pain score assessment at twelve hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Pain score in post op period at 24 hour.

Time Frame: [24 hour]

Pain score assessment at twenty four hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Pain score in post op period at 48 hour.

Time Frame: [48 hour]

Pain score assessment at forty eight hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Pain score in post op period at 72 hour.

Time Frame: [72 hour]

Pain score assessment at seventy two hour by utilizing the Numeric Pain Intensity Scale (NPIS), score will be between 0-10.

Secondary Outcomes

  • Patient Satisfaction(First 30 post-operative days)
  • 4. Emergency visit for pain symptoms by the patients in the postoperative period after the discharge(First 30 post-operative days)
  • Hospital pain killers refill visits of patients for each category of analgesic used(30 post-operative days)

Study Sites (1)

Loading locations...

Similar Trials